Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Roivant Sciences (ROIV) Equity Average: 2021-2025

Historic Equity Average for Roivant Sciences (ROIV) over the last 5 years, with Sep 2025 value amounting to $4.8 billion.

  • Roivant Sciences' Equity Average fell 16.16% to $4.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 billion, marking a year-over-year decrease of 16.16%. This contributed to the annual value of $5.4 billion for FY2025, which is 17.72% down from last year.
  • Per Roivant Sciences' latest filing, its Equity Average stood at $4.8 billion for Q3 2025, which was down 3.82% from $5.0 billion recorded in Q2 2025.
  • In the past 5 years, Roivant Sciences' Equity Average registered a high of $6.5 billion during Q1 2024, and its lowest value of $1.3 billion during Q3 2023.
  • Moreover, its 3-year median value for Equity Average was $5.0 billion (2025), whereas its average is $4.3 billion.
  • Its Equity Average has fluctuated over the past 5 years, first slumped by 37.09% in 2022, then spiked by 331.44% in 2024.
  • Over the past 5 years, Roivant Sciences' Equity Average (Quarterly) stood at $2.3 billion in 2021, then slumped by 37.09% to $1.5 billion in 2022, then surged by 168.94% to $4.0 billion in 2023, then skyrocketed by 40.53% to $5.6 billion in 2024, then declined by 16.16% to $4.8 billion in 2025.
  • Its Equity Average stands at $4.8 billion for Q3 2025, versus $5.0 billion for Q2 2025 and $5.4 billion for Q1 2025.